AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP

By Scott Flaherty (October 24, 2013, 4:43 PM EDT) -- AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.

AARP, which represents Americans 50 and older and their families, sent a letter to U.S. Trade Representative Michael Froman saying the U.S. should not sign onto a TPP agreement that binds it to a 12-year market exclusivity period for branded biologic medicines, which can be used to treat diseases like cancer and rheumatoid arthritis.

Biologics — medicines developed through biological processes — tend to be more expensive...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!